Joshua Rosenblat, MD, MSc, FRCPC @JD_Rosenblat Twitter profile

Pinned Tweet

Joshua Rosenblat, MD, MSc, FRCPC

9 months

Canada's FIRST #psilcoybin clinical trial: Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin @MedCellPress @UofTPsych @UofT 50day #free full text: Thread - 1/5

33

65

208

Last Seen Profiles

@BinorRaja

@UP0Bwyt5Rl9UpHQ

@BinorRaja

@g_suzuki

@xkashm

@BilalLakehal13

@OneEyedOli

@two_peace_era

@BinorRaja

@excell305

@ZenciT

@Alexand35343498

@Oz7enn

@penyukastw21

@DrDimes7

@ReeseWilli67747

@bokeplokalmalam

@papmantan69_

@ggholic

@bokeplokalmalam

@shahrukhan_sa

@md_bi

@AFN_Updates

@VeSilesto

@BY_Vp00

@brian_ohana5

@botas_leon

@lool_llll

@midas_memory

@marital277

@bokeplokalmalam

@TaconasMSM

@xMlJQt3pUdVexxu

@valleygirlfeet

@ShalondaGo36300

@BinorRaja

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

10 Early Career Researcher (ECR) Grant Writing Tips: A Thread. I have been getting lots of messages and emails asking for tips after our @CIHR_IRSC ECR project grant success. Here are 10 tips that came from a variety of mentors that were very helpful to me. @AcademicChatter

6

66

247

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Welcoming Arya Monroe Rosenblat as the newest member of the Rosenblat lab @UofTPsych (class of 2050). Now to start the on-boarding process, then some data entry, maybe a review paper, will see how it goes. Feeling so grateful. Also can finally justify my #dadjokes

21

1

184

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Incredibly grateful for @UofTPsych funding our high risk high reward study @MDPU_TWH @UHN_Research @CAMHnews : Effects of #Psilocybin in Treatment Resistant #Bipolar Depression To my knowledge, this is the FIRST PEER-REVIEWED GRANT funding a psilocybin trial in #Canada ! 1/3

15

21

177

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

My 1 yo daughter is the happiest person I have ever met, constantly smiling and laughing. As a mood disorder psychiatrist, I can’t help but make some observations on how she does it and see what I can learn from her. 3 main observations: 1/5 🧵

3

12

151

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Amazing study!! Ketamine was noninferior to ECT as therapy for treatment-resistant major depression. With 403 participants these results seem pretty solid

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression | NEJM

Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently used for treatment-resistant major depression, but the comparative effectiveness of the two treatments rema...

www.nejm.org

6

38

151

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

6 months

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

15

31

130

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

Feeling incredibly grateful to receive my first @CIHR_IRSC project grant as NPA. This was my first/only CIHR grant application as NPA but with strong pilot data, an outstanding team @UHN_Research @UofTPsych & mentor (Dr. McIntyre), this multi-site RCT was funded on 1st submission

20

2

128

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

The much anticipated compass trial is now published @NEJM

5

39

122

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 months

Very grateful to be promoted to associate professor @UofTPsych @UofT @UHN_Research @uoftmedicine effective July 1st! Thanks to everyone that provided mentorship and support to help me get to this point

26

1

122

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Second positive phase 3 trial for MDMA for PTSD! This is huge as FDA approval requires 2 positive phase 3 trials and now we have that! So much hope for future of PTSD treatment

MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial

Nature Medicine - Results from the phase 3 placebo-controlled MAPP2 trial show that MDMA-assisted therapy reduces post-traumatic stress disorder (PTSD) symptoms and functional impairment in a...

www.nature.com

3

31

120

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Psilocybin therapy for anorexia

6

21

100

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

6 months

See our new updates @CANMAT_org depression guidelines just published today! Congrats @DrRaymondLam for leading this important update. I am grateful to have contributed as a section co-lead. Checkout the updates to adjunctive treatments:

8

25

102

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Incredibly grateful for our team being awarded $1 million for our study: #Psilocybin -assisted #psychotherapy for treatment-resistant #depression : A randomized phase II clinical trial comparing one versus two #psychedelic doses of psilocybin @UofTPsych @UHN @CAMHnews @CIHR_IRSC

CIHR

@CIHR_IRSC

1 year

Minister of Mental Health and Addictions Carolyn Bennett announced funding for 3 clinical trials to study psilocybin-assisted psychotherapy for alcohol use disorder, treatment-resistant depression and end-of-life distress in cancer patients.

2

6

18

15

5

97

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

See our report on the Antidepressant Effects of #Psilocybin in the Absence of #Psychedelic Effects @APAPubJournals We present the first in-human evidence to support antidepressant effects of psilocybin independent of 5HT2A and psychedelic effects 1/4

Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects - PubMed

Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects

pubmed.ncbi.nlm.nih.gov

7

29

80

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 months

Incredibly grateful to @CIHR_IRSC for funding our RCT Combining Ketamine with DBT for Suicidality in Individuals with Treatment Resistant Depression and Borderline Personality Disorder Congrats to the whole team! @UHN_Research @CAMHnews @UofTPsych

8

3

79

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Very grateful to receive the Academic Scholars Award from @UofTPsych @researchuoft to protect 1 additional day per week (0.2FTE) to conduct research. This investment from the department will be tremendously helpful. Congrats to all the other awardees too!

19

0

72

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

6 months

What are the changes in recommendations for MDD augmentation (add-on treatments) in the new 2023 @CANMAT_org update? Lets start with comparing the two tables side by side (2016 versus 2023) Full 2023 guidelines here (open access): A thread 1/10

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

6 months

See our new updates @CANMAT_org depression guidelines just published today! Congrats @DrRaymondLam for leading this important update. I am grateful to have contributed as a section co-lead. Checkout the updates to adjunctive treatments:

8

25

102

2

25

74

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

11 months

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis

7

15

67

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Incredibly grateful to be awarded $1 million to study #Psilocybin -assisted therapy for #depression @UofTPsych @UHN @CAMHnews . This federal investment is extremely encouraging that #GoC see the value of this research. Big team effort including @IshratHusain_ and many more 1/3

CIHR

@CIHR_IRSC

1 year

Today, #GoC announced almost $3M for clinical trials for psilocybin-assisted psychotherapy. With 1 in 5 Canadians experiencing #MentalHealth or #SubstanceUse issues each year, we must explore new and innovative ways to help people.

4

27

65

3

4

68

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Rejection & Resilience in Academia: A Thread @AcademicChatter I usually post about our team’s success stories with new publications and grants. I still believe it is important to celebrate and share these, however, I also think it is important to acknowledge the rejections. 1/5

2

6

66

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

See our national @CANMAT_org guidelines on #psychedelics out today @TheCJPsych We hope this report will provide a helpful summary and guidance for clinicians, researchers, patients, regulators and stakeholders. 1/3

6

20

65

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

A huge day for psychedelic research. The fact that @NEJM published this negative study underlines the importance of scrutinizing this emerging area and not only focusing on small positive studies

Trial of Psilocybin versus Escitalopram for Depression | NEJM

Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. In a phase 2, double-blind, randomized, controlled tr...

www.nejm.org

7

19

65

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Incredibly grateful to receive two @CIHR_IRSC grants yesterday as co-I and PI. As an ECR, I have learned that relationships are just as important as scientific rigour. Our team is a family passionate to reject the status quo and insist that mental health outcomes must be better

2

0

62

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Extremely upsetting and disturbing report on horrific actions by psychedelic therapists. While some may say this is just an isolated event, we must reject the inclination to ignore these reports. How can we prevent this from ever happening again? 1/3

Footage of therapists spooning and pinning down patient in B.C. trial for MDMA therapy prompts...

Newly released videos that show two B.C. therapists cuddling, spooning, blindfolding and pinning down a distressed PTSD patient during clinical trials using MDMA have prompted a review of their work...

www.cbc.ca

2

11

62

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

5 months

A meta-analysis of the effects of ketamine on suicidal ideation in depression patients @Nature Ketamine was more effective than placebo (RR = 10.02), esketamine (RR = 4.81) and midazolam (RR = 3.14, 95%CI = 1.19–8.29) at alleviating suicidality

A meta-analysis of the effects of ketamine on suicidal ideation in depression patients

Translational Psychiatry - A meta-analysis of the effects of ketamine on suicidal ideation in depression patients

www.nature.com

1

17

62

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

Excited to share our international consensus on the use of #ketamine in psychiatry published in American Journal of Psychiatry @APAPsychiatric @APAPubJournals Huge congrats to Dr. Roger McIntyre @UofTPsych @UofTNews @UHN_Research

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An...

Replicated international studies have underscored the human and societal costs associated with major depressive disorder. Despite the proven efficacy of monoamine-based antidepressants in major...

psychiatryonline.org

3

18

58

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PsychopharmTips #114 Vaccines do not have known clinically significant interactions with antidepressants, antipsychotics, anxiolytics or mood stabilizers. When offered the vaccine, do not hesitate to be vaccinated if you are taking psyc meds #MedEd @SharkawyMD @BogochIsaac

1

17

56

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Big step for Australia to legalize psychedelics for mental health. I hope there will be careful collection of safety and effectiveness outcomes as it is still early days and the real world data that can come from this will be very important globally

Australia legalises psychedelics for mental health

Approved psychiatrists can now prescribe MDMA and magic mushrooms for disorders like depression.

www.bbc.com

1

14

55

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

grateful to receive my Masters of Science in the mail today. 2021 will be the first year I am not a student after 28 years of training. Big thanks to family, friends and supervisors for the support.

8

0

53

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

This is painfully accurate...

Awais Aftab

@awaisaftab

4 years

Ok, so I made one for psychiatry!🤓 *Types of Psychiatry Papers*

60

549

2K

2

9

52

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

6 months

Lots of great discussion about the errors with this analysis @PloederlM Check out our meta analysis that pooled results from the same trials but we found much smaller effect size because we correctly converted the SE reported in the trials to SD

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis - PubMed

The aim of this review was to determine the effect of psilocybin on depressive symptoms in patients diagnosed with life-threatening illnesses or major depressive disorder. Systematic searches were...

pubmed.ncbi.nlm.nih.gov

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

6 months

Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis

15

31

130

4

17

51

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

@ahmedhankir Welcome to Canada 🇨🇦! We are lucky to have you hear. Come visit our mood disorder clinic in Toronto @MDPU_TWH @UofTPsych @UHN_Research when you get a chance

3

1

48

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

8 months

See our clinical trial results now in print @MedCellPress March issue #Psilocybin assisted psychotherapy for treatment resistant depression

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

9 months

Canada's FIRST #psilcoybin clinical trial: Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin @MedCellPress @UofTPsych @UofT 50day #free full text: Thread - 1/5

33

65

208

8

48

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PsychopharmTips #98 Psyc meds are a DIFFERENT DRUG at a DIFFERENT DOSE. Ex: quetiapine is an off-label sleep aid at 12.5-50mg, antidepressant at 150-300mg, bipolar depression tx at 300-400mg, anti-manic & antipsychotic at 400-800mg. So do not try to treat mania with 50mg #MedEd

1

7

48

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Honoured to rank #6 for expertise in #depression worldwide @expertscapenews @Daily_Experts Big thanks to @UofTPsych @uoftmedicine @UHN_Research @braxiahq for continued support. Biggest thanks to my mentor, Roger McIntyre, ranking #1 in the world!

7

5

45

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PsychopharmTips #119 Venlafaxine (V) & Desvenlafaxine (D) are NOT the same. Many think of these interchangeably, but the evidence for both MDD & anxiety is stronger for V. D has less side effects and interactions, but might not be as effective; see Cipriani et al 2018 #MedEd

2

7

45

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 months

This is a crazy large effect size!!! I really want to see if this is replicated in a larger RCT as this is almost hard to believe. If true, will be huge for the field

JAMA Psychiatry

@JAMAPsych

4 months

In this randomized clinical trial, accelerated intermittent theta-burst stimulation was more effective than sham stimulation for depressive symptom reduction in patients with treatment-resistant bipolar disorder.

3

22

70

7

5

44

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

Huge congrats to Dr. Roger McIntyre @UofTPsych @UHN_Research for an outstanding update on Bipolar Disorder published this week in @TheLancet . Also very grateful to be part of the team of experts co-authoring this paper

2

12

46

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PsychopharmTips #121 There are ZERO clinically relevant drug-drug interactions between COVID vaccines and any psychiatric medications. Best vaccine to get: the first one that is offered to you. Using common sense, avoid making a psyc med change within one week of vaccine

1

16

46

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

My heart is filled with joy and gratitude celebrating the graduation of our first cohort of multidisciplinary #psilocybin therapists. Hearing all the incredible stories of healing and transformation makes me so hopeful for the future of psychiatry and #psychedelics in #Canada

3

6

42

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Pretty concerning statistics suggesting that clinician scientist may be near extinction in the coming years if things do not change. NIH focused article, but same applies in Canada 🇨🇦

Improving Support for Physician Scientists—Mind the (Funding) Gap

With the odds of receiving National Institutes of Health (NIH) funding increasingly daunting, the physician investigator is becoming an endangered species. For instance, the number of principal...

jamanetwork.com

1

17

46

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

2

12

41

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions @UofTPsych @WPA_Psychiatry

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational...

Treatment-resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with demonstrated predictive utility in terms of clinic...

onlinelibrary.wiley.com

1

10

43

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Massive congratulations @rogersmcintyre @UofT @UofTPsych @UofT_DoM @MDPU_TWH for winning the prestigious Colvin Prize @BBRFoundation Amazing mentor. Amazing accomplishment.

2

4

43

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

8 months

Thanks for the interview @Nature on this important topic Ketamine is in the spotlight thanks to Elon Musk — but is it the right treatment for depression?

4

8

42

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Excited to start day 1 of our weekend intensive training with 20 outstanding therapists learning together how to provide #psilocybin assisted therapy. Great multidisciplinary group from diverse backgrounds, all keen to push the field forward together

3

6

42

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Roland Griffiths was an incredible scientists that revolutionized the field of #psychedelics . I have so much respect for him. He also had such a (rare) balanced scientific view. When asked “do you believe in psychedelics?” His response was “I believe in data.” Just perfect

David Nutt

@ProfDavidNutt

1 year

A sad day: my longtime friend and colleague Roland Griffiths died last night after a long battle with cancer during which he showed the inspiring courage and wisdom that characterised his whole career, especially in resurrecting psychedelic research. A truly great scientist.

53

95

763

1

5

40

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Happy New PG Year to all residents @UofTPsych @uoftmedicine @UofTMDprogram @UHN For all the newly minted PGY1s, you got this! My advice to PGY1s: Be keen Be humble Be kind (including to yourself) Sincerely, A PGY8

0

3

43

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PsychopharmTips #120 Do NOT overmedicate fatigue. Fatigue is a symptom of depression/anxiety, but there are MANY other medical+situational causes. First understand the situational context. If someone is exhausted from working >70 hours/wk, the solution is NOT a stimulant 1/5

2

7

41

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PsychopharmTips #113 Treat MDD to full remission. Residual symptoms are the strongest predictor of relapse. Analogy: Putting a fire 85% out. Average time to relapse after achieving full remission is >3 years versus <7 months if residual symptoms are present. #MedEd #psychtwitter

1

6

40

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Congrats to @Sipan_Haikazian , David and the team @MDPU_TWH @UHN_Research @UofTPsych on this timely paper: #Psilocybin -assisted therapy for #depression : A systematic review and meta-analysis Large effects across 13 trials 50 day #free full text:

3

11

37

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

With the new year, I have reflected more on how I can do these three things. Super simple stuff but powerful if you can consistently do these things. Thanks to Arya for being the best happiness role model a psyc dad could ever ask for! HNY all! 5/5

2

0

39

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Concrete answer to a basic assumption. Staying on antidepressants really does reduce the risk of relapse, even when you feel well enough to stop. Interesting to see this published in @NEJM . Nothing fancy, but just a basic question with solid study design

Maintenance or Discontinuation of Antidepressants in Primary Care | NEJM

Patients with depression who are treated in primary care practices may receive antidepressants for prolonged periods. Data are limited on the effects of maintaining or discontinuing antidepressant ...

www.nejm.org

2

10

39

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

Once again, dissociation does not predict antidepressant effects of ketamine. Remains a common misconception

Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine

Psychopharmacology - The relationship between subjective drug experience and antidepressant outcomes for ketamine derivatives is poorly understood but of high clinical relevance. Esketamine is the...

link.springer.com

1

12

37

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Happy mentorversary ⁦ @rogersmcintyre ⁩ 10 years ago had my elective with Drs. McIntyre & Mansur ⁦ @uhn . Supposed to be 1 month but after a decade, grad school, residency, 200 papers, 20 grants +lots of laughs still here ⁦⁦ @MDPU_TWH ⁩ Thanks for an awesome decade!

4

0

38

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Grateful to start this #Psilocybin assisted therapy RCT @braxiahq soon. This is a big win for #Canada ! Some unique aspects include: -option for repeat doses if depression relapses -includes MDD+bipolar depression -no upper limit for failed med trials

Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada's First Multiple-Dose...

/CNW Telbec/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics...

www.newswire.ca

5

6

35

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

Check out our 4 posters @R2RToronto2022 this weekend: -psilocybin assisted therapy for TRD RCT prelim results -psilocybin therapy training program (results from first cohort) -real world evidence of IV ketamine -protocol for upcoming psilocybin for bipolar depression trial

2

11

37

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

Another new psilocybin RCT for depression. Great to see the number of trials by diverse research groups now being published and growing our understanding

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled,...

Background: Several early phase studies have demonstrated that psilocybin-assisted therapy has rapid-acting and persisting antidepressant effects from just one ...

journals.sagepub.com

2

6

36

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

2

3

37

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Recruitment now open

1

9

33

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PTSD is very hard to treat. Great to see new treatment options emerging: 67% responded to IV #ketamine vs 20% in midazolam-control group A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder

0

6

37

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

11 months

Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes A Nonrandomized Controlled Trial

Single Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major...

This open-label nonrandomized open-label trial evaluates the safety and efficacy of single-dose psilocybin with psychotherapy for depressive episodes in individuals with bipolar disorder.

jamanetwork.com

10

4

34

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Great to see it out in print now!

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Congrats to @Sipan_Haikazian , David and the team @MDPU_TWH @UHN_Research @UofTPsych on this timely paper: #Psilocybin -assisted therapy for #depression : A systematic review and meta-analysis Large effects across 13 trials 50 day #free full text:

3

11

37

0

4

36

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

10 months

Merry Christmas to my fellow clinical trialists around the world! May your holiday season have zero SAEs and your new year filled with p-values less than 0.05 🎅

2

35

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

This is hilarious. On a more serious note, I wish there was better recognition of co-first authorship. Large projects have >1 person slaving away, truly leading the project & deserving first author. The * doesn’t mean much and ppl talk about the “real” 1st author #AcademicChatter

2

6

33

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders

FDA warns about compounded ketamine for psychiatric disorders

www.fda.gov

2

10

36

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PsychopharmTips #99 Do not overuse mirtazapine. Too often I see mirtazapine Rx for MDD+insomnia. Insomnia is a sx of MDD and does not mean automatically select mirtazapine; it can be a helpful med but also has ++weight gain, AM grogginess, dry mouth/eyes so be cautious #MedEd

2

4

36

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Ketamine and ECT in Depression — Risks and Rewards @NEJM

Ketamine and ECT in Depression — Risks and Rewards | NEJM

Investigators from five referral clinics for electroconvulsive therapy (ECT) report in the Journal the results of an open-label, randomized, noninferiority trial of ECT or ketamine infusion in pati...

www.nejm.org

2

5

32

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Is #ketamine a mood stabilizer? Incredibly grateful for PSI foundation funding our multi-site trial: Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression @UofTPsych @UHN_Research @uoftmedicine

Funded Research - PSI Foundation

Grants & Awards funded by PSI Foundation

www.psifoundation.org

3

4

32

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

Massive congratulations to my outstanding 1st year grad students @UHN @UofTPsych with 100% success rate (3/3) all being awarded CGS M federal grants from @CIHR_IRSC . Filled with supervisor joy, despite some other challenging times this week. Here they are (see thread 1/4):

5

0

32

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

See our trial @UHN_Supportive @UHN_Research @PMResearch_UHN just published in Cancers Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study)

A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer...

Antidepressants require several weeks for the onset of action, a lag time that may exceed life expectancy in palliative care. Ketamine has demonstrated rapid antidepressant effects, but has been...

pubmed.ncbi.nlm.nih.gov

1

10

31

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

@Rachbcooper Absolutely agree! I often use a method called “free writing” and find it super useful to just get going. Learned this in ENG100 Effective Writing @UofT and helped me more than most of my bio courses. Very helpful to quickly reveal your gaps in knowledge

Free writing - Wikipedia

en.m.wikipedia.org

1

4

34

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

#PsychopharmTips #123 Do NOT routinely order ECGs when starting antidepressants #MedEd #ECG monitoring is recommended before and following the start of QTc-prolonging antidepressants ONLY in the presence of known vulnerability to QTc prolongation or two or more risk factors 1/3

2

9

34

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

#PsychopharmTips #128 Discussing mechanism of action (MOA) is part of informed consent. Too often I hear MDs say "we have no idea how antidepressants work" providing zero explanation for MOA. Ppl deserve to know about MOA, even if much is unknown/unclear #medtwitter #MedEd 1/4

2

3

33

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

#PsychopharmTips #130 Don't overmedicate. That's it. That's the tweet.

3

6

30

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Come check out our keynote plenary this morning on #psilocybin @CPA_APC @UofTPsych

5

2

31

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

9 months

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review

8

9

32

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Excited to start this clinical trial in the coming months: Integrated Internet-Based Cognitive Behavioural Therapy (i-CBT) & IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial Read more here:

0

1

32

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

Real World Effectiveness of Repeated #Ketamine Infusions for Treatment-Resistant #Depression with Comorbid #Borderline Personality Disorder 50 days #free access to full text:

3

8

32

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

Massive congrats to @bengoldstein73 and the team on completion of this incredibly innovative trial on nitrous oxide in bipolar depression @CAMHnews @CAMHResearch @Sunnybrook @UofTPsych !!!

Proof‐of‐concept randomized controlled trial of single‐session nitrous oxide treatment for refrac...

Background There remain few efficacious treatments for bipolar depression, which dominates the course of bipolar disorder (BD). Despite multiple studies reporting associations between depression...

onlinelibrary.wiley.com

1

5

32

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

Merry Christmas! Heading to the hospital now to cover the psych ER & CL psych services for the holidays. While I can't see my family this year, I am very thankful to be with my hospital family and to still have a job. And thanks to all the other HCWs working these holidays!

1

0

31

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PsychopharmTips #75 In patients with medical comorbidity, pay special attention to side effect profile that can be helpful or harmful depending on the individual/comorbidity/physical sx. See table for examples of key side effects in this group (From: )

0

10

30

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Feeling very grateful to receive this funding and lead this important multi-site RCT evaluating #ketamine for bipolar depression with a great team @UHN_Research @UofTPsych at

2

31

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Very excited to head across the pond today to discuss important developments in #ketamine research @UniofOxford . Grateful for the invitation and opportunity to participate in this world class conference

Braxia

@braxiahq

3 years

Braxia Scientific CEO & CMO, Invited to Speak as Experts at the Ketamine & Related Compounds 2022 International Conference hosted by University of Oxford, April 4-6 - #ketamine #psilocybin #ptsd #depression #therapy #Research #MentalHealth

1

2

12

2

4

29

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

Check out our free teaching session on practical #psychopharmtips for management of treatment resistant depression @UofTPsych TRD: Practical Management

Dr. Josh Rosenblat: TRD: Practical Management

Title: TRD: Practical ManagementEvent: Mood Disorders, ADHD and Obesity: Converging Neuroscience, Clinical Overlap and Novel Treatments Date: October 24th, 2...

www.youtube.com

0

10

32

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

2 years

MAPS PBC Announces Positive Topline Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for Treatment of PTSD

0

9

32

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Huge congrats to Dr. Yena Lee for defending her PhD thesis today. Grateful to have the opportunity to be an examiner and see her incredible work. Dr. Lee published >150 articles during her PhD, likely more than any PhD student in the history of @researchuoft @UofTNews @UHN

2

1

29

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Massive congratulations to the second cohort of our #psilocybin assisted therapy training program for graduating last night. Also celebrating the completion of our first psilocybin RCT with results coming soon to a journal near you!

6

1

28

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 years

Huge congrats to everyone matching to @UofTPsych yesterday! Looking forward to meeting the next gen of psychiatrists in July! #CARMS2022 #CaRMSMatch Key #residency tips: Be keen, be humble and be kind (to those around you and to yourself) Other tips? #psychtwitter #MedEd

2

0

30

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PsychopharmTips #52 Many psyc meds (antipsychotics, mood stabilizers) require monitoring but it is hard to remember what is required when. See the monitoring guidelines () Helpful to have this figure somewhere easy to find in your office or computer

0

10

30

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

10 months

Wow looks like Shoppers Drug Mart is now forcing you to see the pharmacist for a consult for previously shelved items (presumably so that they can bill OHIP). 20 people in line with 1-2 hour wait on Christmas Eve just to get an OTC med. Pharmacist friends, am I missing something?

13

6

31

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

#PsychopharmTips #91 Prescribers must be humble as psychiatric medications are far from perfect. Provide hope but never false hope. We don’t know who will respond and who will get that rare awful side effect. The art & science of psychopharmacology starts with humility.

0

6

30

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

10 months

First day of our new grad course on mood disorders MSC1005 @UofTIMS @UofT @MDPU_TWH @UofTPsych with Dr. Rodrigo Mansur kicking the year off with a comprehensive lecture on pathophysiology of mood disorders. Great to see full class of the next generation of scientists!

0

2

30

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

I have been asked many times how it could be mechanistically possible to have benefits from psilocybin without 5HT2A/psychedelic effects (as shown in our case report ) This well done study shows a very plausible mechanism with direct BDNF effects

Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects | American Journal of...

PsychiatryOnline.org is the platform for all American Psychiatric Association Publishing journals, DSM, and bestselling textbooks, as well as APA Practice Guidelines, and continuing medical education.

psychiatryonline.org

Eero Castren

@castren_eero

1 year

Please check our latest paper . LSD and psilocin are high-affinity ligands of TrkB, sensitizing TrkB to BDNF, promoting plasticity, but not hallucinations. Huge thanks to all the co-authors, especially @RafaelMoliner , @p_casarotto and Ilpo Vattulainen.

20

121

473

2

29

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

1 year

Massive congrats @rogersmcintyre @UofT @UofTPsych on this impressive RCT!! Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial

Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial

In a randomized, double-blind, placebo-controlled study, McIntyre et al. examine the effects of vortioxetine—a multimodal antidepressant—on cognition, mood

academic.oup.com

1

9

30

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

3 months

Great new study with more evidence to support superiority of rTMS to standard treatment for TRD @APApsychiatric rTMS as a Next Step in Antidepressant Nonresponders: A Randomized Comparison With Current Antidepressant Treatment Approaches

1

8

30

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

4 years

Been a challenging few days on call @UHN but been incredibly impressed by countless nurses, residents, staff MDs, support and cleaning staff coming together to care for our patients over the holidays. Your compassion and work ethic is overwhelming.

1

0

30

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

5 months

Wow, this is shocking!!! Looking like FDA might not be approving MDMA for PTSD?!?

5

3

29

Joshua Rosenblat, MD, MSc, FRCPC

@JD_Rosenblat

8 months

The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder @PLOSONE

8

2

28